Chloroquine and Hydroxychloroquine is an antimalarial, disease-modifying anti-rheumatic drug. In China and France, some studies provided some indications of possible benefits against pneumonia caused by COVID-19 but need confirmation through randomized trials.
There are many trials going on now to test the efficacy of these drugs. Mechanism of action of hydroxychloroquine includes multiple effects including reduced cytokine production, inhibits immune activation and also interferes with lysosomal activity and membrane stability.
Chloroquine was discovered in 1934 by Hans AndersagIt is usually available as a generic medication. Common side effects include muscle problems, loss of appetite, diarrhoea, and skin rash and serious side effects include problems with vision, muscle damage, seizures, and low blood cell levels. It is a member of the drug class 4-aminoquinoline.
During pregnancy, a woman undergoes with multiple interactions with the health care system that increases her chance of getting infected. So therefore, managing pregnant population presents a unique challenge during COVID-19. The physiological changes and partial immune suppression during pregnancy makes pregnant women and new-born babies susceptible to several infections. Post-partum haemorrhage, maternal sepsis, preeclampsia, and premature rupture of membrane are the most common COVID-19-induced adverse events reported among pregnant women.
Title : Nanomaterial-mediated systemically-administered m-rna-based Gene therapy directed exclusively to cancer, resulting in eradication of implanted orthotopic tumors with no side effects
A C Matin, Stanford University, United States
Title : Mucoadhesive electrospun fibers in oral drug delivery
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Qualitative and quantitative measures of drugs’ placenta permeability - a chromatographic and computational approach
Anna Weronika Sobańska, Medical University of Lodz, Poland
Title : The signification of the blood-brain barrier to the transfer of essential and toxic mineral elements
Bartolome Ribas Ozonas, Royal National Academy of Pharmacy, Spain
Title : New excipient to formulate poorly soluble APIs
Rajendran Arunagiri, Eastman, United States
Title : Multi-detection of pharmaceutical contamination in environment
Andreia Freitas, INIAV and REQUIMTE, Portugal
Title : HDAC inhibitors with non-hydroxamate warhead
Franz Josef Meyer Almes, University of Applied Sciences, Germany
Title : The role of non-antibiotic drugs on the development of antibiotic resistance
Mujde Eryilmaz, Ankara University, Turkey
Title : Digital health: Education in clinical pharmacy and implementation in practice
Aysu selcuk, Ankara University, Turkey
Title : Pharmacovigilance – Important, current trends, challenges and opportunities
Gurpreet Singh, Freyr Lifesciences Limited, United Kingdom